Clinical Trial Update: Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing bioavailability of mycophenolate mofetil products in stable renal transplant recipients; study terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection
• Renal Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Myfenax (mycophenolate mofetil)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Stable Renal Transplant Recipients | Phase 4 | Status: TERMINATED | Results posted: 2013-07-30